Penumbra ROE 2014-2022 | PEN
Current and historical return on equity (ROE) values for Penumbra (PEN) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Penumbra ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2022-09-30 |
$-0.03B |
$0.97B |
-3.21% |
| 2022-06-30 |
$-0.02B |
$0.97B |
-2.24% |
| 2022-03-31 |
$-0.01B |
$0.96B |
-0.86% |
| 2021-12-31 |
$0.00B |
$0.95B |
0.68% |
| 2021-09-30 |
$0.03B |
$0.69B |
5.14% |
| 2021-06-30 |
$0.02B |
$0.67B |
2.48% |
| 2021-03-31 |
$-0.00B |
$0.65B |
-0.79% |
| 2020-12-31 |
$-0.02B |
$0.64B |
-2.70% |
| 2020-09-30 |
$-0.01B |
$0.62B |
-1.80% |
| 2020-06-30 |
$0.01B |
$0.62B |
1.94% |
| 2020-03-31 |
$0.04B |
$0.49B |
8.23% |
| 2019-12-31 |
$0.05B |
$0.49B |
10.63% |
| 2019-09-30 |
$0.05B |
$0.47B |
10.34% |
| 2019-06-30 |
$0.02B |
$0.45B |
3.72% |
| 2019-03-31 |
$0.01B |
$0.44B |
2.84% |
| 2018-12-31 |
$0.01B |
$0.42B |
1.44% |
| 2018-09-30 |
$0.01B |
$0.41B |
1.94% |
| 2018-06-30 |
$0.03B |
$0.43B |
6.65% |
| 2018-03-31 |
$0.01B |
$0.42B |
3.05% |
| 2017-12-31 |
$0.00B |
$0.40B |
1.05% |
| 2017-09-30 |
$-0.01B |
$0.38B |
-2.00% |
| 2017-06-30 |
$0.01B |
$0.37B |
1.58% |
| 2017-03-31 |
$0.01B |
$0.37B |
3.50% |
| 2016-12-31 |
$0.02B |
$0.27B |
5.96% |
| 2016-09-30 |
$0.02B |
$0.25B |
7.40% |
| 2016-06-30 |
$0.01B |
$0.25B |
2.53% |
| 2016-03-31 |
$0.00B |
$0.24B |
1.14% |
| 2015-12-31 |
$0.00B |
$0.23B |
0.87% |
| 2015-06-30 |
$-0.00B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$9.289B |
$0.748B |
|
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.
|
